Oligodendroglioma is a slow-growing brain tumor defined by a specific pair of genetic changes: a combined loss of chromosome arms 1p and 19q (called 1p/19q codeletion) plus a mutation in one of the IDH genes. These molecular features are not just useful markers; since 2016, they are the diagnostic requirement. A tumor that looks like an oligodendroglioma under the microscope but lacks these genetic signatures is classified as something else entirely. That molecular definition matters because oligodendrogliomas tend to respond better to treatment and carry a longer survival outlook than most other adult brain tumors, though “longer” still means years to decades of monitoring, treatment decisions, and quality-of-life trade-offs.
What Makes an Oligodendroglioma an Oligodendroglioma
For most of brain tumor history, pathologists classified gliomas by how their cells looked under a microscope. Oligodendroglioma cells have a distinctive “fried egg” appearance with round nuclei and clear halos, plus a network of branching blood vessels sometimes described as a chicken-wire pattern. These features were the basis for diagnosis for decades. But different pathologists looking at the same tissue sample often disagreed, and it became clear that tumors with similar appearances could behave very differently depending on their genetics.
The shift came when researchers discovered that the combined deletion of chromosome arms 1p and 19q was especially common in tumors that looked and acted like classic oligodendrogliomas. This codeletion, paired with a mutation in the IDH1 or IDH2 gene, became the molecular criterion that now defines the diagnosis.1PubMed Central. Diagnostic accuracy of 1p/19q codeletion tests in oligodendroglioma: A comprehensive meta-analysis based on a Cochrane systematic review The whole-arm nature of this codeletion is distinctive and results from an unusual chromosomal rearrangement: an unbalanced translocation that swaps material between chromosomes 1 and 19, leaving each daughter cell with one arm missing from each.2PubMed Central. Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1
On top of those two core changes, oligodendrogliomas almost always carry additional mutations. The TERT promoter, which helps control how cells maintain their chromosomal end-caps, is mutated in roughly 97% of cases.3PubMed Central. The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas Mutations in the CIC gene, located on chromosome 19q, are also frequent and appear to cooperate with the IDH mutation to alter levels of a metabolic byproduct called 2-hydroxyglutarate (2HG), which in turn influences how tumor cells grow and divide.4PubMed Central. Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity The picture that emerges is not a tumor caused by a single genetic event but one shaped by a consistent constellation of changes.
Where These Tumors Come From
Oligodendrogliomas are named after oligodendrocytes, the brain cells that produce the insulating myelin sheath around nerve fibers. The natural assumption was that these tumors arise from mature oligodendrocytes. Research has pushed the origin story back a step: the tumor cells more closely resemble oligodendrocyte progenitor cells (OPCs), which are the precursor cells that normally develop into oligodendrocytes. Studies in both mice and humans have found that OPC markers, rather than neural stem cell markers, enrich for tumor-forming ability in oligodendroglioma tissue.5PubMed Central. Non-stem cell origin for oligodendroglioma MRI data from the same research suggested a white-matter origin, consistent with where OPCs reside in the brain. Separate molecular work confirmed that oligodendroglioma cells express genes characteristic of the oligodendrocyte lineage, reinforcing the link to these progenitor cells.6PubMed. Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors
This progenitor-cell origin has a practical implication. OPCs are more therapy-sensitive than neural stem cells, which partly explains why oligodendrogliomas tend to respond better to chemotherapy and radiation than gliomas that originate from stem cells higher up the developmental ladder.7PubMed Central. Non-stem cell origin for oligodendroglioma There is also growing evidence that oligodendroglioma cells can form functional synapses with neurons, borrowing the normal signaling machinery of OPCs to support their own growth. This neuron-glioma crosstalk is an active area of research and could eventually open up new treatment angles.8PubMed Central. Neuron-Glial Interactions in Health and Brain Cancer
Symptoms and How It Looks on Imaging
Oligodendrogliomas grow slowly enough that patients often have symptoms for years before being diagnosed. The most common presenting symptom is seizures, which makes sense given the tumor’s strong tendency to involve the cortex, the outer gray-matter layer of the brain.9PubMed. Oligodendroglioma and its variants: radiologic-pathologic correlation Headaches are the other frequent early complaint. In one imaging study of 35 untreated cases, the average age at presentation was around 35, and calcification within the tumor was common.10PubMed. Intracranial oligodendrogliomas: imaging findings in 35 untreated cases Hemorrhage and cystic areas within the tumor were seen in a fair number of cases as well.
On MRI, oligodendrogliomas typically show up as a mass involving the cortex and underlying white matter, often in the frontal lobe. Calcification, which is easily spotted on CT scans, is one of the imaging hallmarks. The tumor borders tend to be somewhat indistinct, and lower-grade tumors generally do not enhance with contrast dye, though higher-grade ones may. The presence of contrast enhancement can signal a more aggressive biology, which has led researchers to investigate whether specific genetic mutations are linked to that imaging feature.
Surgery and the Value of Removing More Tumor
Surgery is typically the first step in managing an oligodendroglioma. The goal is to remove as much tumor as safely possible without causing new neurological problems. A growing body of evidence supports the idea that more extensive resection translates into better outcomes. One analysis of grade 3 oligodendrogliomas found that having a subtotal resection or biopsy instead of a gross total resection was associated with roughly four times the risk of death, making extent of resection one of the strongest predictors of survival alongside the patient’s functional status and whether they had persistent neurological deficits after surgery.11Neuro-Oncology Advances. An expanded role for surgery in grade 3 1p/19q co-deleted oligodendroglioma A separate volumetric study found that reducing the tumor volume by more than 80% was positively correlated with both overall and progression-free survival.12PubMed Central. Analysis of outcomes of patients with oligodendroglioma with focus on volumetric reduction
Because oligodendrogliomas infiltrate into surrounding brain tissue, achieving a complete resection is not always possible, especially when the tumor sits in or near areas that control language, movement, or other critical functions. Awake craniotomy, where the patient performs tasks during surgery to help the surgeon map functional areas, is commonly used in these cases. The surgical philosophy has shifted toward maximal safe resection: take out as much tumor as you can while protecting the patient’s quality of life.
Chemotherapy and Radiation
After surgery, treatment decisions hinge on the tumor grade and how much was left behind. For grade 2 (lower-grade) oligodendrogliomas, there has been a longstanding debate about when to start additional treatment versus watching and waiting. A landmark trial settled much of that debate by showing that radiation combined with PCV chemotherapy (procarbazine, CCNU, and vincristine) produced dramatically longer survival than radiation alone: a median overall survival of about 13 years compared with about 8 years. The 10-year overall survival rates were 60% versus 40%. Having oligodendroglioma histology was identified as a favorable factor for both progression-free and overall survival.13PubMed Central. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
PCV is not the only chemotherapy regimen used. Temozolomide (TMZ), an oral drug that is easier to tolerate, has become widely used in neuro-oncology. However, head-to-head comparisons suggest PCV may be superior for oligodendroglioma specifically. One study found that patients treated with PCV had a median progression-free survival of about 9 years, compared with roughly 3.6 years for those on temozolomide, and only 1 out of 30 PCV-treated patients progressed from grade 2 to grade 3.14PubMed Central. PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression Another analysis comparing the two approaches found a median time to recurrence of 12 years with PCV versus 4.7 years with TMZ, though after adjusting for other variables, the overall survival difference was no longer significant.15Neuro-Oncology. NCMP-11. ASSESSING SURVIVAL OUTCOMES OF PCV-BASED AND TEMOZOLOMIDE-BASED ADJUVANT THERAPY IN OLIGODENDROGLIOMA PATIENTS The side-effect burden between the two regimens was similar. Pending more definitive clinical trial results, many specialists lean toward PCV as the preferred option for this tumor type.
Vorasidenib and the New Era of Targeted Treatment
The IDH mutation that defines oligodendroglioma has become a therapeutic target. Vorasidenib is an oral drug that crosses the blood-brain barrier and inhibits the mutant IDH enzyme, blocking the production of the oncometabolite 2HG. In the INDIGO phase 3 trial, vorasidenib roughly tripled the time before tumors progressed compared with placebo. Median progression-free survival was about 28 months in the vorasidenib group versus about 11 months with placebo, and the time to next intervention (meaning the next surgery, radiation, or chemotherapy) was similarly extended.16PubMed Central. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
Updated data from the trial, with six additional months of follow-up, were even more encouraging. Median progression-free survival in the vorasidenib arm had not yet been reached, meaning more than half of treated patients still had not progressed. Meanwhile, tumors in the vorasidenib group were actually shrinking at an average rate of about 1% per assessment, while placebo-treated tumors were growing at roughly 14% per assessment.17The Lancet Oncology. Vorasidenib in grade 2 IDH-mutant low-grade glioma (INDIGO): a extension of safety and efficacy data from a randomised, double-blind, placebo-controlled, phase 3 trial Vorasidenib was approved by the FDA in 2024 and represents the first targeted therapy for IDH-mutant gliomas. It is used for grade 2 tumors after surgery, particularly in situations where doctors want to delay radiation and its long-term side effects.
Monitoring Treatment Response Without Surgery
One of the challenges in managing any brain tumor is distinguishing real tumor growth from treatment-related changes on imaging. Radiation and chemotherapy can cause tissue damage that mimics tumor progression on MRI, a phenomenon broadly called pseudoprogression or treatment-related necrosis.18PubMed. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment Making the wrong call in either direction has consequences: if you mistake necrosis for tumor growth, you might subject a patient to unnecessary reoperation. If you mistake true progression for a treatment artifact, you lose time.
An emerging tool is magnetic resonance spectroscopy (MRS) to detect 2HG, the metabolite produced by the mutant IDH enzyme. Because 2HG is specifically produced by the tumor, tracking its levels offers a way to monitor the tumor that does not depend on interpreting ambiguous MRI images. Early studies showed that 2HG could be reliably detected non-invasively in IDH-mutant tumors.19PubMed Central. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas Follow-up research confirmed the clinical utility: 2HG concentrations dropped rapidly in 1p/19q-codeleted oligodendrogliomas during treatment, and those levels reliably reflected the disease state over time.20PubMed Central. Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma As vorasidenib and similar drugs that directly target the IDH pathway become more widespread, this kind of metabolic monitoring could become routine.
When Oligodendrogliomas Become More Aggressive
Despite their generally favorable prognosis, oligodendrogliomas can progress to higher-grade disease over time. The same 1p/19q codeletion and IDH mutation persist throughout the tumor’s life, but additional genetic hits accumulate. Researchers have identified mutations in the NOTCH1 pathway as particularly worrisome: NOTCH1-mutant oligodendrogliomas showed higher cellular density and were strongly associated with contrast enhancement on imaging, a surrogate for more aggressive behavior.21npj Precision Oncology. Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways Mutations in the PI3K pathway also trended in the same direction.
Treatment itself can sometimes contribute to progression. Analysis of tumors that recurred after long-term temozolomide treatment found that the recurrent tumors had acquired new mutations in DNA repair genes, leading to a hypermutation phenotype where the tumor’s mutation rate skyrockets.22PubMed Central. Genomic alterations of oligodendrogliomas at distant recurrence In one patient, this treatment-driven hypermutation was associated with rapid disease progression. This is a known risk of prolonged alkylating chemotherapy and one reason clinicians carefully weigh how long to continue temozolomide. DNA methylation profiling is being explored as a way to grade oligodendrogliomas more objectively, potentially catching aggressive biology before it manifests clinically.23Acta Neuropathologica. DNA methylation analysis reveals an epigenetic signature distinctive of high-grade oligodendroglioma
Living with an Oligodendroglioma Long Term
Because oligodendroglioma patients often survive for many years or even decades, long-term quality of life is not a secondary concern. It is, in many ways, the central one. A large international study found that clinically meaningful impairment was common even among survivors who were doing well by oncological standards. More than half reported impaired cognitive functioning on quality-of-life scales, about half reported emotional difficulties, and around 45% reported significant fatigue.24PubMed Central. Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: An international cross-sectional investigation Objective neuropsychological testing confirmed these concerns, with problems in verbal memory affecting close to half of patients.
Among long-term survivors of higher-grade (anaplastic) oligodendroglioma, cognitive outcomes are quite variable. In one study, about a quarter of progression-free patients had no cognitive impairment, while about 30% were severely impaired. Despite this, about 80% of long-term survivors could live independently.25PubMed. Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors Importantly, both the tumor and its treatment contribute to cognitive decline. Structural brain imaging of long-term survivors showed significant gray-matter atrophy and white-matter changes, and the degree of cognitive impairment tracked with the extent of those brain changes.26PubMed Central. Cognitive and brain structural changes in long-term oligodendroglial tumor survivors Patients who had received more treatment, particularly radiation, tended to show more structural damage. This is exactly why delaying radiation in lower-risk patients, using surgery and chemotherapy first, has become a common strategy.
Oligodendroglioma in Children
Pediatric oligodendrogliomas are rare and biologically distinct from the adult form. While adult oligodendrogliomas are defined by their 1p/19q codeletion and IDH mutation, tumors in children often lack both of these molecular features.27Academic Press. Pediatric oligodendroglioma This means the treatment strategies and prognostic frameworks developed for adults do not straightforwardly apply. Pediatric brain tumors are increasingly classified by their own molecular profiles, and a tumor that looks like an oligodendroglioma under the microscope in a child may turn out to be a fundamentally different disease at the genetic level. The practical takeaway for families is that molecular testing is even more critical in children than adults, because the treatment plan hinges on what the tumor actually is rather than what it looks like.
The rarity of pediatric oligodendroglioma also means there is far less clinical trial data to guide treatment decisions. Most of the landmark trials that established PCV-based chemotherapy and radiation protocols enrolled adults. Pediatric neuro-oncologists typically rely on extrapolation from adult data, institutional experience, and smaller case series. Research into the distinct molecular drivers of pediatric gliomas is ongoing, with the hope of identifying targeted therapies similar to what vorasidenib has become for IDH-mutant tumors in adults.